Overview

68Ga-P3 PET/CT Imaging in Malignancy

Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. [68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Phase:
N/A
Details
Lead Sponsor:
Peking University First Hospital